Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice

Human Molecular Genetics

Volumn 23, Issue 18, 2014, Pages 4960-4969

  Wenqiang, Chen ^a,b   Lonskaya, Irina ^a   Hebron, Michaeline L ^a   Ibrahim, Zainab ^b   Olszewski, Rafal T ^b   Neale, Joseph H ^b   Moussa, Charbel E H ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANILINE DERIVATIVE; BOSUTINIB; DNA BINDING PROTEIN; NITRILE; PARKIN; PROTEIN KINASE INHIBITOR; PROTEIN TDP-43; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ANIMAL; CELL NUCLEUS; COGNITION; CYTOPLASM; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOTOR PERFORMANCE; MOUSE; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; UBIQUITINATION;

ANILINE COMPOUNDS; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; COGNITION; CYTOPLASM; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, TRANSGENIC; MOTOR SKILLS; NEURONS; NITRILES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84906834507     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu211     Document Type: Article

References (35)

1. Rowland, L.P. and Shneider, N.A. (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med., 344, 1688-1700.
2. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
3. Polymenidou, M., Lagier-Tourenne, C., Hutt, K.R., Huelga, S.C., Moran, J., Liang, T.Y., Ling, S.C., Sun, E., Wancewicz, E., Mazur, C. et al. (2011)Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci., 14, 459-468.
4. Buratti, E. and Baralle, F.E. (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator ofCFTRexon 9. J. Biol. Chem., 276, 36337-36343.
5. Ou, S.H., Wu, F., Harrich, D., Garcia-Martinez, L.F. and Gaynor, R.B. (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TARDNAsequence motifs. J. Virol., 69, 3584-3596.
6. Winton, M.J., Igaz, L.M., Wong, M.M., Kwong, L.K., Trojanowski, J.Q. and Lee, V.M. (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem., 283, 13302-13309.
7. Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y.M. and Baralle, F.E. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem., 280, 37572-37584.
8. Mackenzie, I.R., Rademakers, R. and Neumann, M.(2010)TDP-43 andFUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol., 9, 995-1007.
9. Mackenzie, I.R., Bigio, E.H., Ince, P.G., Geser, F., Neumann, M., Cairns, N.J., Kwong, L.K., Forman, M.S., Ravits, J., Stewart, H. et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol., 61, 427-434.
10. Kwiatkowski, T.J. Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T. et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205-1208.
11. Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323, 1208-1211.
12. Song, J.H., Huang, C.S., Nagata, K., Yeh, J.Z. and Narahashi, T. (1997) Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J. Pharmacol. Exp. Ther., 282, 707-714.
13. Wokke, J. (1996) Riluzole. Lancet, 348, 795-799.
14. Lonskaya, I., Hebron, M.L., Desforges, N.M., Franjie, A. and Moussa, C.E. (2013) Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol. Med., 5, 1247-1262.
15. Hebron, M.L., Lonskaya, I. and Moussa, C.E. (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum. Mol. Genet., 22, 3315-3328.
16. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G.J., Nicolini, F.E., O'Brien, S.G., Litzow, M. et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110, 3540-3546.
17. de Lavallade, H., Apperley, J.F., Khorashad, J.S., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. et al. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol., 26, 3358-3363.
18. Lonskaya, I., Hebron, M.L., Desforges, N.M., Schachter, J.B. and Moussa, C.E. (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J. Mol. Med. (Berl)., 92, 373-386.
19. Lagier-Tourenne, C., Polymenidou, M., Hutt, K.R., Vu, A.Q., Baughn, M., Huelga, S.C., Clutario, K.M., Ling, S.C., Liang, T.Y., Mazur, C. et al. (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci., 15, 1488-1497.
20. Hebron, M., Chen, W., Miessau, M.J., Lonskaya, I. and Moussa, C.E. (2014) Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis. J. Neurochem., 129, 350-361.
21. Hebron, M.L., Lonskaya, I., Sharpe, K., Weerasinghe, P.P., Algarzae, N.K., Shekoyan, A.R. and Moussa, C.E. (2013) Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J. Biol. Chem., 288, 4103-4115.
22. Goldberg, M.S., Fleming, S.M., Palacino, J.J., Cepeda, C., Lam, H.A., Bhatnagar, A., Meloni, E.G., Wu, N., Ackerson, L.C., Klapstein, G.J. et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem., 278, 43628-43635.
23. Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V., Ceuterick-de Groote, C., Van Broeckhoven, C. and Kumar-Singh, S. (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA, 107, 3858-3863.
24. Wegorzewska, I., Bell, S., Cairns, N.J., Miller, T.M. and Baloh, R.H. (2009) TDP-43mutant transgenic mice develop features ofALSand frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA, 106, 18809-18814.
25. Che, M.X., Jiang, Y.J., Xie, Y.Y., Jiang, L.L. and Hu, H.Y. (2011) Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J., 25, 2344-2353.
26. Arai, T., Hasegawa, M., Nonoka, T., Kametani, F., Yamashita, M., Hosokawa, M., Niizato, K., Tsuchiya, K., Kobayashi, Z., Ikeda, K. et al. (2010) Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology, 30, 170-181.
27. Lonskaya, I., Desforges, N.M., Hebron, M.L. and Moussa, C.E. (2013) Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. PLoS One, 8, e83914.
28. Herman, A.M., Khandelwal, P.J., Rebeck, G.W. and Moussa, C.E. (2012) Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models. Exp. Neurol., 235, 297-305.
29. Kang, H. and Schuman, E.M. (1996) A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science, 273, 1402-1406.
30. Martin, K.C., Casadio, A., Zhu, H., Yaping, E., Rose, J.C., Chen, M., Bailey, C.H. and Kandel, E.R. (1997) Synapse-specific, long-term facilitation of aplysia sensory to motor synapses: a function for local protein synthesis in memory storage. Cell, 91, 927-938.
31. Huber, K.M., Kayser, M.S. and Bear, M.F. (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science, 288, 1254-1257.
32. Vincent, A., Briggs, L., Chatwin, G.F., Emery, E., Tomlins, R., Oswald, M., Middleton, C.A., Evans, G.J., Sweeney, S.T. and Elliott, C.J. (2012) parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum. Mol. Genet., 21, 1760-1769.
33. Rebeck, G.W., Hoe, H.S. and Moussa, C.E. (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J. Biol. Chem., 285, 7440-7446.
34. Lonskaya, I., Shekoyan, A.R., Hebron, M.L., Desforges, N., Algarzae, N.K. and Moussa, C.E. (2013) Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer's disease. J. Alzheimers Dis., 33, 231-247.
35. D'Hooge, R. andDeDeyn, P.P. (2001) Applications of theMorriswatermaze in the study of learning and memory. Brain Res. Brain Res. Rev., 36, 60-90.